1 / 30

Hepatitis C virus Treatment

Hepatitis C virus Treatment. Ermias D (MD). Over view. 1989 – first case of documented HCV treatment with interferon α Normalization of ALT, but high rate of relapse interferon and ribavirin Favorable response, but still in less than half Measure of treatment success Biochemical,

von
Download Presentation

Hepatitis C virus Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C virus Treatment Ermias D (MD)

  2. Over view • 1989 – first case of documented HCV treatment with interferon α • Normalization of ALT, but high rate of relapse • interferon and ribavirin • Favorable response, but still in less than half • Measure of treatment success • Biochemical, • virologic, • histologic • Evaluation period: • end of tx response, • sustained tx response

  3. Acute infection • Justification to tx • Tx gives sustained virologic response in > 85% • With out tx high rate of progression to chronic phase • Limited efficacy of tx in chronic infection • Drawbacks • High rate of side effects • Optimal tx regimen ? --- like the chronic • Best point of intervention ? • Diagnosing acute infection

  4. Supportive care • hospitalization for severe illness • Restrict physical activity • High calorie diet • Cholestatic and hepatotoxic drugs should be avoided • Cholestyramine for severe pruritis • Glucocorticoids – no value • Physical isolation/handling care – bleeding patients • Discharge as sx regress and decreasing trend of enzymes • Fulminant cases – hemodynamic support, electrolyte balance, glycemic control, control of bleeding, coma care, lactulose/neomycine, low protein, • Extracorporal liver assist device • liver transplantation

  5. Chronic infection • All pts may warrant tx • Clear indication • Chronic HCV infection with detectable HCV RNA (10-50IU) • Elevated amino transferase enzymes (N not excluded) • Histologic evidence of progressive liver disease – more than portal fibrosis stage (Ishak or Metavir) • No additional serious coexisting condition or contraindication for tx • Eradication of virus is associated with improvement in quality of life even in the absence of liver disease • Decreased ds progression from compensated - decompensated cirrhosis – HCC • combination tx > monotx • Decompensated cirrhosis – unlikely to respond

  6. Regimens • Monotx with IFNα (48wk) - initial response 40%, sustained response <20%, specially for genotype 1 • INFα + ribavirin – increased sustained response from 16 to 40% • Two large prospective trials showed • HCV genotype 2 or 3; low viral loads – required 24 wks of tx for optimal outcome • Genotype 1 and high viral load required 48 wks for optimal outcome • Genotype and pretx viral load determine duration of tx • At 24wks PCR HCV RNA – if positive dc tx - no tx response • Genotype 2 and 3, with negative PCR Viral RNA can stop tx at 24 wks • Other genotypes and negative PCR assay need additional 24 wks tx

  7. Compared to HBV • HCV tx • No transient acute hepatitis • ALT fall precipitously during tx • 90% virologic response seen in first 12 wks • Durable virologic response for 5-6yrs in successful tx, normal ALTand improved histology ----- almost cure

  8. Good prognosis • Low baseline viral load < 2million c/ml • Histologically mild hepatitis, minimal fibrosis • Favorable genotype 2, 3 than 1, 4 • Age <40 yrs • Non obese • Female • White population • >80% adherance • Brief duration of infection • Low HCV quasispecies diversity • Immunecompetence • Low liver iron level

  9. Interferon α • Cytokine • Attach on cell surface receptor • Signal Janus activated kinase and signal transducers and activate transcription, induction of genes • Double stranded RNases, viral protein inhibitors, destabilisers of viral messanger RNA • Immune response genes – activation of natural killer cells, maturation of dendritic cells, proliferation of memory T cells, prevention of T cell apoptosis • Increased drug dose and rapid infected hepatocyte death is related to rapid viral clearance • INF α 3million IU sc 3X/wk before bed time

  10. Adverse effects of Tx • INFα • Muscle ache, fatigue, depresion, anxiety, irritability, sleep disturbance, concentration difficulty • Autoimmune rxn – thyroiditis, • alopecia, rashes, diarrhea, numbness • Serious side effects permanent injury and death 1-2% from combination • Pt information and monthly check ups – sx and cbc • 30-40% require dose reduction, 20% discontinuation

  11. ribavirin • Oral nucleoside analogue • Mech against HCV not clear • Minimal direct activity • Lead to rapid and lethal mutation of virions • Depletion of intracellular guanosine triphosphase necessary for viral RNA synthesis • Has immune modulatory effects • Dose - 1200mg for >75Kg/ - 1000mg for <75Kg in two divided doses • Hemolysis, anemia (ACS, stroke), teratogenic • Nasal, chest congestion, pruritis, ppt gout

  12. contraindications • Absolute • Pregnancy, lactation, allergy to the drugs • Relative • Decompensated cirrhosis • Bilirubin >1.5mg/dl • PT > 15sec • INR >1.7 • Albumin <3.4g/dl • Ascites • Bleeding esophageal varices • Hepatic encephalopathymajor neuropsychiatric disease • Coronary or CVD • Renal failure • Solid organ transplant • Recent alcohol abuse • Anemia, leukopenia, thrombocytopenia

  13. Pegylated interferon • Polyethylene glycol attachment to INFα • Extended half life, given once a wk • Dose depend on wt • Higher response rate than the conventional tx with INF α+ ribavirin • Peg INF-α 2a and 2b • Comparable efficacy, • INF α 2a well tolerated

  14. responses • Sustained virologic response • 75-80% in genotype 2 and 3, • 40-50% in genotype 1, • lower response among blacks than white (28 vs 52%), • poor response in initial high viral load >600,000iu/ml, male, obese, advanced liver fibrosis • Transient virologic response, • relapse 20%, breakthrough 10% • Reappearance of HCV RNA, rise in ALT, common with short coarse tx and monotherapy • Non response • HCV RNA remain detectable and ALT remain raised • Common with genotype 1 (30%), rare in genotypes 2, 3.

  15. Tx of ribavirin contraindication • PegINF α • Also for 20% of pt who after combination tx develop ribavirin induced anemia Retreatment • Relapse or non response after standard INF monotx or with ribavirin • PegIFN α +Ribavirin • Tx for non responders to PegIFN +Ribavirin – no available tx, need controlled clinical trials. • High dose IFN induction, amantadine, maintenance tx,….. Maintenance tx • Cutaneous vasculitis, GN ass with HCV • ?? Relapses, non responses

  16. Areas of uncertainity • Tx for children • Tx acute hepatitis C • >85% virologic response if tx initiated in 6 months time • Or 75% progress to chronic phase • High side effects in acute tx • Improving side effects and cost (30-40,000USD) • Futile to continue tx in genotype 1 if RNA positive at 24wk • Prediction – If no 2log10IU/ml viral drop or undetectable by 12 wk --- 98-100% non response • Rapid response – HCV RNA negative by 4 wk, dc at 12-16 wk for genotype 2, 3 and at 24 for genotype 1 and low level HCV RNA

  17. Liver transplant • For decompensated HCV related cirrhotic pts, and early stage HCC • Reinfection of graft – inevitable • Accelerated disease progression (in immuno suppressed) • Pre and post transplant viral suppression, • New tx needed • Similar 1 and 5 yr survival rate with other liver transplant cases ??

  18. Co infection with HIV1 • Increased risk of disease progression • Tx early regardless of ALT, histology • Poor rates of response to monotherapy like HCV infection alone • Similar efficacy as a lone HCV with combination tx • HAART – immune reconstitution, hepatotoxic drugs – exacerbate hepatitis • Initiat tx for HCV before HAART

  19. Potential target for future drug development • HCV proteases • helicase • Polymerase • Internal ribosomal entry site • Putative cell surface receptor CD81 • Newer INF

  20. prevention • Ineffective Ig, vaccine - - immunoprophylaxis not feasible • Chemoprophylasis – none Universal precautions • Screening transfusion blood and blood products • Sterile interventional materials • Avoid sharing razor blade, nail clippers…. • Avoid multiple sexual partnership, use barriers • No fear in stable monogamous sexual partners • No special precaution for babies from infected mothers • No restriction of breast feeding

  21. thank you

More Related